Glutamine Plus L. Reuteri Prevents TKI Therapy-diarrhea in Patients With NSCLC

This open-label randomized clinical trial aims to evaluate the glutamine plus Lactobacillus reuteri supplementation effect in a standard-of-care diet in EGFR mutant patients with advanced non-small cell lung cancer (NSCLC) under tyrosine kinase inhibitors (TKIs) therapy. The main question it aims to answer is ¿What is the effect of glutamine plus L. reuteri added to an astringent diet in preventing diarrhea generated by TKI therapy? Patients will receive an astringent diet supplemented with 10 grams of glutamine and L. reuteri (100 million CFU). Researchers will compare the Glutamine plus L. reuteri diet with a standard astringent diet to see if TKI therapy diarrhea is prevented.

NCT Number	NCT05852990
Lead Sponsor	Instituto Nacional de Cancerologia de Mexico
Conditions	Non-Small Cell Lung Cancer With EGFR Mutation
Enrollment	28 participants
Start Date	2022-03-01
Primary Completion	2026-12-01 (estimated)
Study Completion	2027-12-12 (estimated)
Updated on ClinicalTrials.gov	2026-04-09